Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-2 and UCBT for Refractory AML
NCT00871689Phase 2
Key facts
- Status
- Terminated
- Start
- Jan 2009
- Primary completion
- Mar 2010
- Countries
- 1
- Sponsor
- Masonic Cancer Center
- Modality
- Cytokines & Interferons
- Drugs
- aldesleukin
- Conditions
- acute myeloid leukemia (AML)
01
Overview
Phase 2, open-label trial of aldesleukin in acute myeloid leukemia (AML), sponsored by Masonic Cancer Center. Primary endpoint: Number of Patients With Neutrophil Engraftment at Day 42. Started Jan 2009; status: terminated.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Patients aged 0-45 with relapsed or refractory AML, including primary induction failure or high-risk CR1/CR2, with acceptable organ function and no active infection.
04
Endpoints
Primary
Number of Patients With Neutrophil Engraftment
Beyond the preview
Go deeper on NCT00871689.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00871689.